RC
KROS icon

Rangeley Capital’s Keros Therapeutics KROS Stock Holding History

Rangeley Capital’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$582K Hold
54,400
– – 0.53% 51
2026
Q1 		$601K Sell
54,400
-42,400
-44% -$655K 0.58% 43
2025
Q4 		$1.97M Sell
96,800
-161,819
-63% -$2.84M 1.64% 18
2025
Q3 		$4.09M Sell
258,619
-26,781
-9% -$396K 3.54% 8
2025
Q2 		$3.81M Sell
285,400
-122,834
-30% -$1.66M 4.55% 6
2025
Q1 		$4.16M Buy
+408,234
New +$4.74M 4.46% 6

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Rangeley Capital's KROS Position: Q2 2026 in Review

Rangeley Capital held its Keros Therapeutics (KROS) position steady in Q2 2026 at 54,400 shares worth $582K. The position accounts for 0.53% of the portfolio, ranked #51.

Rangeley Capital first reported a position in KROS in Q1 2025 and has held it in 6 quarters since. The position peaked at $4.16M in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Rangeley Capital held 54,400 shares of Keros Therapeutics worth $582K as of Q2 2026.
  • Rangeley Capital left its Keros Therapeutics share count unchanged in Q2 2026.
  • Keros Therapeutics made up 0.53% of Rangeley Capital's portfolio in Q2 2026, its #51 holding.
  • Rangeley Capital first reported a position in Keros Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Rangeley Capital's Keros Therapeutics position peaked at $4.16M in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.